Abstract
NLRP3 inflammasome has recently attracted much attention as a potentially druggable target to develop potential therapeutics for inflammatory and neurodegenerative disorders. In our continuing studies, structure–activity relationship studies were conducted based on a newly identified NLRP3 inhibitor, YQ-II-128, from our laboratory to understand the structural features and improve aqueous solubility. The results revealed that steric interactions at the propoxyl and amide domain of YQ-II-128 are important for the observed inhibitory potency on the NLRP3 inflammasome. The results also identified the amide domain to incorporate polar moieties to improve solubility and potentially pharmacokinetic properties. As a result, analog 10 was identified as a selective NLRP3 inhibitor with comparable potency while significantly improved aqueous solubility. Collectively, these findings strongly encourage further optmization of 10 to develop analogs with improved pharmacokinetic properties as potential NLRP3-targted therapeutics.
Similar content being viewed by others
Data accessibility
The datasets supporting this article have been included and could be found in the manuscript.
References
Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10:417–26. https://doi.org/10.1016/S1097-2765(02)00599-3
Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140:821–32. https://doi.org/10.1016/j.cell.2010.01.040
Malik A, Kanneganti T-D. Inflammasome activation and assembly at a glance. J Cell Sci. 2017;130:3955–63. https://doi.org/10.1242/jcs.207365
Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013;13:397–411. https://doi.org/10.1038/nri3452
Shao B-Z, Xu Z-Q, Han B-Z, Su D-F, Liu C. Nlrp3 inflammasome and its inhibitors: a review. Front Pharmacol. 2015;6:262. https://doi.org/10.3389/fphar.2015.00262
Kelly N, Jeltema D, Duan Y, He Y. The NLRP3 inflammasome: an overview of mechanisms of activation and regulation. Int J Mol Sci. 2019;20:3328. https://doi.org/10.3390/ijms20133328
Rowczenio DM, Gomes SM, Aróstegui JI, Mensa-Vilaro A, Omoyinmi E, Trojer H, et al. Late-onset cryopyrin-associated periodic syndromes caused by somatic NLRP3 mosaicism-UK single center experience. Front Immunol. 2017;8:1410. https://doi.org/10.3389/fimmu.2017.01410
Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet. 2001;29:301–5. https://doi.org/10.1038/ng756
De Nardo D, Latz E. NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol. 2011;32:373–9. https://doi.org/10.1016/j.it.2011.05.004
Choi AJS, Ryter SW. Inflammasomes: molecular regulation and implications for metabolic and cognitive diseases. Mol Cells. 2014;37:441–8. https://doi.org/10.14348/molcells.2014.0104
Couturier J, Stancu IC, Schakman O, Pierrot N, Huaux F, Kienlen-Campard P, et al. Activation of phagocytic activity in astrocytes by reduced expression of the inflammasome component ASC and its implication in a mouse model of Alzheimer’s disease. J Neuroinflammation. 2016;13:20. https://doi.org/10.1186/s12974-016-0477-y
Freeman LC, Ting JP-Y. The pathogenic role of the inflammasome in neurodegenerative diseases. J Neurochem. 2016;136:29–38. https://doi.org/10.1111/jnc.13217
Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, et al. Nlrp3 is activated in Alzheimer’s disease and contributs to pathology in App/Ps1 Mice. Nature. 2013;493:674–8. https://doi.org/10.1038/nature11729
Venegas C, Kumar S, Franklin BS, Dierkes T, Brinkschulte R, Tejera D, et al. Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease. Nature. 2017;552:355–61. https://doi.org/10.1038/nature25158
Lazaridis L-D, Pistiki A, Giamarellos-Bourboulis EJ, Georgitsi M, Damoraki G, Polymeros D, et al. Activation of NLRP3 inflammasome in inflammatory bowel disease: differences between Crohn’s disease and ulcerative colitis. Dig Dis Sci. 2017;62:2348–56. https://doi.org/10.1007/s10620-017-4609-8
Feist E, Burmester GR. Canakinumab for treatment of cryopyrin-associated periodic syndrome. Expert Opin Biol Ther. 2010;10:1631–6. https://doi.org/10.1517/14712598.2010.530653
Kelly A, Ramanan AV. A case of macrophage activation syndrome successfully treated with anakinra. Nat Clin Pract Rheumatol. 2008;4:615–20. https://doi.org/10.1038/ncprheum0919
Gillespie J, Mathews R, McDermott MF. Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS). J Inflamm Res. 2010;3:1–8. https://doi.org/10.2147/JIR.S8109
Zhang X, Xu A, Lv J, Zhang Q, Ran Y, Wei C, et al. Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases. Eur J Med Chem. 2020;185:111822. https://doi.org/10.1016/j.ejmech.2019.111822
Coll RC, Robertson AAB, Chae JJ, Higgins SC, Muñoz-Planillo R, Inserra MC, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21:248–55. https://doi.org/10.1038/nm.3806
Jiang H, Hongbin H, Chen Y, Huang W, Cheng J, Ye J, et al. Identification of selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med. 2017;214:3219–38. https://doi.org/10.1084/jem.20171419
Wang S, Yang H, Yu L, Jin J, Qian L, Zhao H, et al. Oridonin attenuates Aβ1-42-indicued neuroinflammation and inhibits NF-κB pathway. PLoS ONE. 2014;9:e104745. https://doi.org/10.1371/journal.pone.0104745
Huang Y, Jiang H, Chen Y, Wang X, Yang Y, Tao J, et al. Tranilast directly targets NLRP3 to treat inflammasome-driven diseases. EMBO Mol Med. 2018;10:e8689. https://doi.org/10.15252/emmm.201708689
He Y, Varadarajan S, Muñoz-Planillo R, Burberry A, Nakamura Y, Núñez G. 3,4-Methylenedioxy-β-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. J Biol Chem. 2014;289:1142–50. https://doi.org/10.1074/jbc.M113.515080
Marchetti C, Swartzwelter B, Gamboni F, Neff CP, Richter K, Azam T, et al. OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc Natl Acad Sci. 2018;115:E1530–39. https://doi.org/10.1073/pnas.1716095115
Cocco M, Pellegrini C, Martínez-Banaclocha H, Giorgis M, Marini E, Costale A, et al. Development of an acrylate derivative targeting the NLRP3 inflammasome for the treatment of inflammatory bowel disease. J Med Chem. 2017;60:3656–71. https://doi.org/10.1021/acs.jmedchem.6b01624
Fulp J, He L, Toldo S, Jiang Y, Boice A, Guo C, et al. Structural insights of benzenesulfonamide analogues as NLRP3 inflammasome inhibitors: design, synthesis, and biological characterization. J Med Chem. 2018;61:5412–23. https://doi.org/10.1021/acs.jmedchem.8b00733
Perera AP, Fernando R, Shinde T, Gundamaraju R, Southam B, Sohal SS, et al. MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice. Sci Rep. 2018;8:8618. https://doi.org/10.1038/s41598-018-26775-w
Xia S, Zhang X, Li C, Guan H. Oridonin inhibits breast cancer growth and metastasis through blocking the Notch signaling. Saudi Pharm J. 2017;25:638–43. https://doi.org/10.1016/j.jsps.2017.04.037
Sato S, Takahashi S, Asamoto M, Naiki T, Naiki-Ito A, Asai K, et al. Tranilast suppresses prostate cancer growth and osteoclast differentiation in vivo and in vitro. Prostate. 2009;70:229–38. https://doi.org/10.1002/pros.21056
Marchetti C, Swartzwelter B, Koenders MI, Azam T, Tengesdal IW, Powers N, et al. NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis. Arthritis Res Ther. 2018;20:169. https://doi.org/10.1186/s13075-018-1664-2
Yin J, Zhao F, Chojnacki J, Fulp J, Klein WL, Zhang S, et al. NLRP3 inflammasome inhibitor ameliorates amyloid pathology in a mouse model of Alzheimer’s disease. Mol Neurobiol. 2018;55:1977–87. https://doi.org/10.1007/s12035-017-0467-9
Jiang Y, He L, Green J, Blevins H, Guo C, Harsiddhbhai S, et al. Discovery of second-generation NLRP3 inflammasome inhibitors: design, synthesis, and biological characterization. J Med Chem. 2019;62:9718–31. https://doi.org/10.1021/acs.jmedchem.9b01155
Brand S, Norcross NR, Thompson S, Harrison JR, Smith VC, Robinson DA, et al. Lead optimization of a pyrazole sulfonamide series of Trypanosoma brucei N-myristoyltransferase inhibitors: identification and evaluation of CNS penetrant compounds as potential treatments for stage 2 human African trypanosomiasis. J Med Chem. 2014;57:9855–69. https://doi.org/10.1021/jm500809c
Acknowledgements
The work was supported in part by the NIA of the NIH under award number R01AG058673 (SZ), Alzheimer’s Drug Discovery Foundation 20150601 (SZ).
Author information
Authors and Affiliations
Contributions
YX and MS performed organic synthesis and biological characterization. HB tested the solubility. SZ designed the research. SZ and YX wrote the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Xu, Y., Scipioni, M., Blevins, H. et al. Structural insights of sulfonamide-based NLRP3 inflammasome inhibitors: design, synthesis, and biological characterization. Med Chem Res 30, 473–482 (2021). https://doi.org/10.1007/s00044-020-02692-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-020-02692-4